Revance Therapeutics Scores $33M in Series E Financing
Revance Therapeutics Inc., a specialty biopharmaceutical company, has raised raised $33 million of its Series E growth financing, the company announced Tuesday. In addition, Revance announced the conversion of $71 million in convertible debt into the Series E preferred stock. Money will go toward clinical trials as well as other growth efforts. Revance’s investors include Essex Woodlands, NovaQuest Pharma Opportunities Fund, Delphi Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Bio*One Capital and Pac-Link Ventures, and Palo Alto Fund.
2 April 2013•2 mins read
